People · Operator
Named in public records as an officer, director or promoter · active 2014–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Deka Biosciences, Inc. | — | Biotechnology | Series B | $45.7M | $387.8M | 2023 |
| Paragon Bioservices, Inc. | — | Biotechnology | Series A | $22.9M | $180.8M | 2014 |
Peter Buzy at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Peter Buzy on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Lucio Iannone | 1 | 6 |
| Kapila Ratnam | 1 | 5 |
| Detlev Biniszkiewicz | 1 | 4 |
| CHRISTOPHER KERSEY | 1 | 2 |
| Rakhshita Dhar | 1 | 2 |
| DONALD HUGHES | 1 | 2 |
| Robert Roche | 1 | 2 |
| John Mumm | 1 | 1 |
| Pavel Khrimian | 1 | 1 |
| Lu Han | 1 | 1 |
| Christopher Yaen | 1 | 1 |
| Vera Mumm | 1 | 1 |
| Sally (Yuanheng) Wang | 1 | 1 |
| Patrick Hervy | 1 | 1 |
| Marco Chacon | 1 | 1 |
| Christian Kanady | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.